New York State Teachers Retirement System Trims Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

New York State Teachers Retirement System decreased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 5.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 72,162 shares of the company's stock after selling 4,273 shares during the period. New York State Teachers Retirement System owned approximately 0.09% of IDEXX Laboratories worth $29,835,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of IDXX. International Assets Investment Management LLC boosted its stake in IDEXX Laboratories by 52,746.0% during the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock worth $2,669,890,000 after acquiring an additional 527,460 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock worth $179,867,000 after acquiring an additional 316,048 shares in the last quarter. Seilern Investment Management Ltd bought a new stake in IDEXX Laboratories during the fourth quarter worth about $113,104,000. Vontobel Holding Ltd. boosted its stake in IDEXX Laboratories by 90.1% during the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company's stock worth $173,051,000 after acquiring an additional 198,404 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC boosted its stake in IDEXX Laboratories by 230.1% during the third quarter. Worldquant Millennium Advisors LLC now owns 110,196 shares of the company's stock worth $55,673,000 after acquiring an additional 76,809 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of IDXX traded up $1.93 during mid-day trading on Wednesday, hitting $450.99. 499,898 shares of the company traded hands, compared to its average volume of 704,909. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The stock has a 50-day moving average price of $430.91 and a two-hundred day moving average price of $452.43. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The stock has a market cap of $36.93 billion, a price-to-earnings ratio of 42.27, a P/E/G ratio of 3.35 and a beta of 1.37.

Analyst Ratings Changes

IDXX has been the topic of several research reports. Piper Sandler boosted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Barclays upped their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, February 5th. Morgan Stanley dropped their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Finally, Leerink Partnrs upgraded shares of IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and an average price target of $533.75.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares of the company's stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,330 shares of company stock valued at $6,161,276. Insiders own 2.18% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.